Introduction
While progress has been made over the last decades in the field of tumor immunology, the earlier optimism on the clinical application of currently available cancer vaccines have been met with some disappointments. 1 This has prompted research on alternative immune-based strategies that may mediate cancer regression in preclinical and clinical models. Although only few patients have been treated, different types of cell transfer studies are currently in focus as some protocols have demonstrated regression of cancers in mice and humans. [2] [3] [4] [5] [6] [7] Clearly, increased efforts in the development of new protocols for cancer immunotherapy are needed, including settings involving adoptive transfer of clinical grade immune cells.
Natural killer (NK) cells constitute approximately 10-15% of the lymphocytes in human peripheral blood. Their cytolytic activity, as well as their secretion of cytokines and chemokines, are crucial components of the innate immune defense. [8] [9] [10] Triggering of NK cell effector functions is stimulated by specific cytokines as well as activating signals transmitted by specific cell-surface receptors upon interaction with target cells. NK cell activation receptors recognize cellular stress-inducible proteins such as MIC-A, MIC-B, ULBP1-4 and other, as yet, not characterized molecules. NK cell activation is counteracted by NK cell inhibitory receptors recognizing mainly MHC class I molecules on target cells. [11] [12] [13] As a consequence NK cells normally spare MHC class I expressing cells, whereas they can kill cells that have lost the expression of MHC class I molecules provided the target cell expresses ligands for activation receptors, a condition often seen in malignant transformation and/or virus infection. 14 The potential therapeutic implications of NK cells have been increasingly recognized in recent years. In part, this is a consequence of an increased understanding of how NK receptor-ligand matching influences lysis of target cells including tumor cells. Clinical evidence furthermore indicates that NK cells play a role in the outcome of patients undergoing hematopoietic stem cell transplantation. For example, the number of circulating NK cells is significantly lower in patients with chronic myeloid leukemia (CML) who relapsed after hematopoietic stem cell transplantation than in those who remained in remission. 15 Alloreactive NK cells can provide antileukemia effects leading to improved survival in patients undergoing haploidentical allogeneic stem cell transplantation for acute myeloid leukemia. 16 Finally, adoptive transfer of over night activated human haploidentical NK cells was recently shown to have a potential role in treatment of acute myeloid leukemia (AML). 7 These findings have prompted a further analysis of the potential usage of NK cells in human immunotherapy. We have recently described a new protocol for efficient expansion of human NK cells from the peripheral blood of healthy donors under good manufacturing practice-(GMP-) conditions (clinical grade). 17 NK cells have also been successfully expanded under similar conditions from B-cell chronic lymphocytic leukemia (B-CLL) patients, indicating the potential of the procedure for the generation of NK cells for autologous cellular immunotherapy. 18 In the present study, we have evaluated the safety and antileukemia therapeutic efficacy of the present ex vivo 
Materials and methods

Animals
SCID-beige mice, 8-10 weeks of age, on a CB17 background (MTC, Karolinska Institutet, Stockholm, Sweden) were housed in microisolator cages in a specific pathogen-free environment. Food, water and bedding were autoclaved before use. All animal procedures were approved by the local departments as well as by the Committee for Animal Ethics in Stockholm, Sweden.
Tumor cell culture
The K562 cell line was grown in vitro in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. The cultures were replenished with fresh medium every 2-3 days throughout the culture period, and replaced by new cells from the frozen stock after 8-10 in vitro passages.
In vitro expansion and purification of human NK cells
The in vitro culture conditions for the expansion of NK cells from PBMCs have been previously described. 17 Briefly, PBMCs were isolated from buffy-coats of healthy blood bank donors by gradient centrifugation, using Lymphoprep (Nyegaard, Oslo, Norway). After washing twice with phosphate-buffered saline (PBS) (Gibco, Grand Island, NY, USA), cells were cultured in tissue culture flasks (Falcon by Becton Dickinson, Le Pont de Claix, France) at 2.5 Â 10 5 cells/ml. CellGro SCGM serum-free medium (CellGenix, Freiburg, Germany) with the addition of 5% human serum (Sigma, St Louis, MO, USA) and 500 U/ml IL-2 (Peprotech, London, UK), was used in all cultures. During the first 5 days of culture, the medium was supplemented with anti-CD3 antibody (Orthoclone OKT-3, Ortho Biotech Inc, Raritan, NJ, USA) to a final concentration of 10 ng/ml. On days 5-6, the medium was replaced with fresh medium containing 5% human serum and IL-2 (500 U/ml), but not OKT-3. Cultures were replenished with fresh medium every 2-3 days throughout the culture period of 21 days. Total cell numbers were assessed by trypan blue staining on days; 0, 5-6, 9-10, 14-15 and 19-21. Absolute cell counts were calculated by multiplying the total number of cells in each subset with the percentage of these subsets determined by flow cytometry. Cell phenotype was analyzed during and at the end of the expansion period according to standard procedures previously described. 18 For experiments with purified NK cells, NK cell purification was performed at the end of the culture period by depleting T cells with anti-human CD3 beads using CD3 MicroBeads and MiniMACSt with a LS Column from Miltenyi (Miltenyi Biotec GmbH, Germany). The isolated NK cell population had a purity of 495% (CD3 À CD56 þ ).
Injection and detection of human effector cells in SCID-beige mice
Two different approaches were used to track the enriched NK cell preparation after intravenous i.v. injection into the mice. NK cells were either radio-labeled with 111 Indium-oxide ( 111 In) and detected by a g-camera or prestained with the fluorescent dye carboxyfluorescein-diacetate-succinimydil-ester (CFSE) and traced by FACS analysis in single cell-suspensions derived from mouse tissues. For radiolabeling, cells obtained on day 21 of human PBMC culture were labeled with 111 In for 30 min at 371C, washed three times with PBS, and resuspended in PBS to a final concentration of 1 Â 10 8 cells/ml in PBS. Radiolabeled cells (10-20 Â 10 6 ) were infused into the tail vein of irradiated (2 Gy) SCID-beige mice under anesthesia (pentobarbital 7 mg/100 g body weight given intraperitoneally). 111 In-labeled cells were detected with a three-headed g-camera, TRIAD XLT 20 (Trionix Research Laboratory Inc, Twinsburg, OH, USA) at the time of cell injection (1 image/min, during 30 min), 24 and 48 h later (1 image/5 min, during 15 min). The resulting images were analyzed on a HERMES system (Hermes Medical Solutions, Stockholm, Sweden). For labeling with fluorescent dye, cells obtained on day 21 of human PBMC culture were labeled with CFSE (10 mM in PBS) for 15 min at 371C, 19 washed once in serum containing media and resuspended in PBS to a final concentration of 1 Â 10 8 cells/ml. Labeled human effector cells (20 Â 10 6 ) were then injected i.v. to the tail vein of irradiated (2 Gy) SCID-beige mice. At days 2, 4 and 9 after injection, single cellsuspensions of the bone marrow, spleen, blood, lung and liver were prepared and incubated with appropriated concentrations of human-specific, direct-labeled antibodies (Becton Dickson, Mountain View, CA, USA) for CD56 or HLA-ABC molecules. After incubation for 30 min, cells were washed and resuspended with PBS. Data acquisition was performed with FACSCalibur (Becton Dickson), and the analysis with Cell Quest software. In each sample a minimum of 1 Â 10 5 cells was acquired.
Injection and detection of K562 cells in SCID-beige mice
To study tumor cell distribution, K562 cells were labeled with CFSE (10 mM in PBS) for 15 min at 371C, 19 washed once in medium containing serum and resuspended in PBS to a final concentration of 5 Â 10 6 cells/ml. 10 6 CFSE labeled cells were injected into the tail vein of irradiated (2 Gy) SCID-beige mice. After 5 and 24 h from injection, a single cell-suspension of the bone marrow, spleen, blood, lung and liver was prepared. The organ cell suspension was then used to detect CFSE-labeled tumor cells by FACS analysis. In each sample a minimum of 5 Â 10 5 cells was acquired.
Injection of K562 cells and ex vivo expanded NK cells to SCID-beige mice CML was induced by i.v. injection of 1 Â 10 6 K562 cells into sub-lethally irradiated (2 Gy) mice. In order to evaluate the in vivo antitumor activity of ex vivo expanded human NK cells, mice (n ¼ 10) were injected i.v. with 20 Â 10 6 effector cells obtained on day 21 of human PBMC culture one day after K562 cell injection. Mice were, thereafter, observed daily for signs of morbidity. The control groups included mice injected i.v. with tumor cells (n ¼ 15); mice injected with expanded NK cell preparation (n ¼ 8) and mice injected with PBS (n ¼ 8) alone. Sick mice were killed when presented a loss of body weight X40% and/or worsening of symptoms. Presence of tumor cells infiltrating tissues of mice was evaluated by FACS analysis of single-cell suspensions from the bone marrow, spleen, blood, lung and liver. Tumor cells were detected by the human-specific antibody for glycophorin A, CD235a (Dako Cytomation, Glostrup, Denmark).
Cytotoxicity assay
The cytotoxic capacity of ex vivo expanded human NK cells (enriched NK cell preparation) was assessed on day 21 of culture using the NK-sensitive K562 cell line as target. Cytotoxic Antileukemia activity of ex vivo expanded human NK cells F Guimarães et al function was measured in a standard 4 h 51 Cr-release assay as previously described. 17 
Statistics
To analyze statistical significance (Po0.05) of the survival curves, statistical analysis was conducted with log rank test using Graph Pad Prism version 3.00 for windows (Graph Pad Software, San Diego, CA, USA).
Results
Phenotype and cytotoxicity of effector cells after ex vivo expansion
After 21 days of culture, the effector cell preparation had expanded B3-log and consisted of a median of 74% (Figure 1a) . The enriched NK cell preparations displayed strong in vitro lytic activity against K562 cells (Figure 1b) . The median cytotoxic activity was 79 and 18% at a 10:1 and 1:1 effector:target cell ratio, respectively. The effector cell preparation used in in vivo studies showed at least 50% lysis against K562 targets in vitro at an 10:1 E:T ratio.
Toxicity, distribution and survival of human ex vivo expanded NK cell effector cells in SCID-beige mice
In vivo experiments revealed no signs of toxicity or other unwanted side effects upon infusion of SCID-beige mice with a high dose (20 Â 10 6 ) of the NK cell enriched effector cell population during an observation time of 100-130 days (eight independent experiments with NK cells from different donors, four mice/group). The therapeutic effectiveness of adoptively transferred effector cells most likely depends on their presence in the tumor infiltrated tissue and on their ability to make contact with target cells. We, therefore, aimed at initially evaluating the distribution of the human NK cell enriched effector cells in non-tumor bearing SCID-beige mice. Ex vivo expanded effector cells were labeled either with the radioisotope 111 In or CFSE fluorescent dye prior to i.v. injection. Human effector cells were detected immediately after injection in the lungs of mice (blue box) and, subsequently, in more inferior regions overlapping with the liver (moving towards the red box). At day 1 post i.v. injection, the 111 In signal was homogeneously distributed over the lower part of the thorax and the upper part of the abdomen (Figure 2a and b) . No major alterations in cellular distribution were observed after day one (data not shown). Figure 3 shows data obtained from FACS analysis of single cell suspensions of mouse tissues, two and four days after injection with CFSE-labeled cells. At day 2, CFSElabeled NK cell enriched human cells were found in high numbers in the lungs and liver and to a lesser extent also in blood, bone marrow and spleen of mice (Figure 3a and b) . At day 4, lung, liver, bone marrow and blood showed lower percentages of CSFE labeled cells (Figure 3a) . After this time point, human effector cells could not any longer be detected by flow cytometry in the mouse tissues.
Injection of K562 cells to SCID-beige mice 1 Â 10 6 K562 cells were injected i.v. into irradiated SCID-beige mice. Distribution of the K562 cells was subsequently studied (three independent experiments, 15 mice in total). Figure 4 shows data from FACS analysis obtained from single-cell suspensions of different mouse tissues at 5 and 24 h following i.v. injection of 1 Â 10 6 CFSE-labeled K562 cells. Leukemia cells were detected in all tissues analyzed 5 h after injection. 24 h after injection, leukemia cells could still be detected in most organs analyzed, but in lower numbers (Figure 4) . Following K562 leukemia cell injection, a period of approximately 6 weeks (40.374.0 days) followed without remarkable alterations in the phenotype of the injected mice. This period was followed In vivo antileukemia activity of ex vivo expanded NK cells
The human effector cells expanded ex vivo were subsequently evaluated for their in vivo antileukemia activity. Effector cells (20 Â 10 6 ) were injected i.v. in SCID-beige mice 24 h after K562 leukemia cell injection. The NK cell enriched effector cell preparation was effective in preventing tumor development, resulting at the end of the observation period (100 days) in a higher number (P ¼ 0.015) of surviving mice in the treated group than in the untreated group ( Figure 5 ). In the untreated group, 50% of the mice were killed within 40-50 days after K562 leukemia cell injection due to tumor development. This number increased to 80% within 80 days after leukemia cell injection. In contrast, 70% of the mice treated with enriched NK cell preparation remained healthy until 100 days after leukemia cell injection. Similar results were obtained with purified NK cells (data not shown). Presence of leukemia cells was confirmed in the blood of untreated mice during the sickness period, whereas in the treated survivor mice, the leukemia cells could not be detected by flow cytometry by staining cells with anti-human CD235a mAb recognizing glycophorin A (data not shown).
Discussion
In the present study, we evaluated the in vivo antitumor activity of human ex vivo expanded clinical grade NK cells in SCIDbeige mice. Administration of NK cells did not show any Antileukemia activity of ex vivo expanded human NK cells F Guimarães et al adverse effects and prevented tumor development, proving in vivo antitumor activity of the present effector cell population.
For the last couple of decades, several attempts have been made to develop immunotherapy for cancer treatment. A significant obstacle to the development of NK cell-based adoptive immunotherapy has been the availability of appropriate cytotoxic cells. In early attempts, so called lymphokineactivated killer (LAK) cells were used in vivo both in animals and humans for the treatment of different types of cancers. [20] [21] [22] [23] [24] This approach was hampered by the relatively low antitumor activity of LAK cells, in part due to relatively low frequencies of NK cells among total LAK effector cells, and in part due to the difficulty of generating large numbers of such cells. 20, [23] [24] [25] [26] We have recently described a protocol for the generation of NK cell enriched effector cells under GMP-conditions. 17, 18 We have in the present study used these cells to evaluate their potential in vivo cytotoxicity in SCID-beige mice. These cells efficiently eliminate K562 leukemia cells in a majority of treated mice.
The combination of low dose total body irradiation followed by i.v. injection of 1 Â 10 6 K562 cells was found to be a good condition for establishment of leukemia in SCID-beige mice. As in human CML, 27 the disease in irradiated SCID-beige mice presented a discontinuous pattern of evolution with a long and variable period without remarkable alterations, which was unpredictably followed by a shorter, less variable and more aggressive phase. Allogeneic stem cell transplantation after chemotherapy or radiation remains the only curative approaches for CML. Restrictions to its applicability are related with the age of the patient and donor availability. 28 Relapses are associated with persistence of leukemic cells after therapy. 28, 29 While CML cells are relatively resistant to cytotoxic drugs and radiation, they are usually sensitive to immunotherapy and particularly to NK cell-mediated cytotoxicity. 30 Therefore, an enriched population of NK cells could be applied as a therapy to eliminate or control residual disease. In our animal model, the number of tumor cells detected in mouse tissues were similar to those found in residual disease. 31 The biodistribution and homing of transfused effector cells is always a critical point for cell therapy approaches. Arrest in lungs with subsequent degradation might take place, thus preventing any therapeutic effect outside of the lungs. If not retained in the lungs, the transfused cells probably migrate to preferred organs. Knowledge of the preferred organs is important for planning new therapeutic strategies with these effector cells. Last, but not least, the migration to tumor sites is considered a prerequisite for therapeutic efficacy. In the present experimental model, radiolabeled effector cells allowed a kinetic study of the biodistribution. Indium labeling of human leukocyte is a common practice in the clinic and it has been shown to be well tolerated by human cells. 32 The human NK cells stained with Indium could be followed during their in vivo. However, quantification of the human NK cells infiltrating different organs is more difficult with this system. For this reason, we labeled the human NK cells with CFSE (a die for live cells). Results were assessed by FACS analysis of CFSE-labeled effector cells, which allowed a quantification of human cells infiltrating specific mouse tissues. FACS analysis showed that the number of human effector cells in the mouse tissues decreased gradually over time, supporting the idea that the life-span of human NK cells in immunodeficient mice might be little longer than 4 days, when cytokines such as IL-2 or IL-15 are not provided. However, providing effector cells with IL-2 during in vivo injection may extend their survival and increase possibilities for tumor eradication. Our data confirmed previous observations with in vitro IL-2 activated NK cells, that is, a tendency of these cells to migrate towards the liver and inflammatory areas. 33, 34 In addition, we also detected CD56
þ human effector cells in the blood and bone marrow of the mice. These observations are in line with a recent study investigating NK cell distribution in renal cell carcinoma patients. Briefly, it was shown that after NK cell transfusion, all patients had circulating donor cells for up to 3 days. After 7 days, all donor cells were cleared from the blood. When investigating whole body distribution, NK cells were detected predominantly in the liver, spleen, and bone marrow, after a short initial predominance in the lungs. 35 It is unlikely that indium or CFSE labeling could impact the distribution or half-life of NK cells. Indium and CFSE bind to the cells in two different ways, 32, 36 but in both cases the results were comparable; indicating that neither of the stainings affected the obtained results.
In summary, our data show that the present ex vivo expanded NK cell enriched effector cell population is safe in vivo and reach tissues infiltrated by tumor cells resulting in significant tumor cell clearance and reduced mortality in SCID-beige mice. The present data validate this protocol for future use in settings of cellular immunotherapy. 
